China Approves New Bispecific Antibody for Advanced Neuroendocrine Carcinoma

China's Center for Drug Evaluation has approved Opamtistomig, a bispecific antibody developed by Leads Biolabs, for the treatment of advanced extrapulmonary neuroendocrine carcinoma. This approval introduces a new monotherapy option for patients battling this specific type of cancer. The drug targets both PD-L1 and 4-1BB pathways.